Subject Characteristics (n = 33)
| Characteristic | No. (%) |
|---|---|
| M/F | 22/11 (66.7/33.3) |
| Age (y) | 54 (31–83) |
| Site | |
| Parotid gland | 22 (66.7) |
| Submandibular gland | 7 (21.2) |
| Minor salivary gland | 4 (12.1) |
| Pathology | |
| Salivary duct carcinoma | 5 (15.2) |
| Mucoepidermoid carcinoma, high grade | 6 (18.2) |
| Squamous cell carcinoma | 3 (9.1) |
| Adenoid cystic carcinoma, solid type | 10 (30.3) |
| Carcinoma ex pleomorphic adenoma | 6 (18.2) |
| Adenocarcinoma | 3 (9.1) |
| TNM stage | |
| T1–T2 | 19 (57.6) |
| T3–T4 | 14 (42.4) |
| N0–N1 | 27 (81.8) |
| N2–N3 | 6 (18.2) |
| M0 | 26 (78.8) |
| M1 | 7 (21.2) |
| Treatment modality | |
| Op + RT | 26 (78.8) |
| Chemotherapy | 7 (21.2) |
| Treatment outcome | |
| NED | 15 (45.5) |
| AWD | 13 (39.4) |
| DOD | 5 (15.2) |
| Follow-up (mo) | 24.3 (12–47) |
| PET/CT and CT work-up (n = 37) | |
| Initial evaluation | 14 (37.8) |
| Follow-up | 23 (62.2) |
Op = operation; RT = radiation therapy; NED = no evidence of disease; AWD = alive with disease; DOD = died of disease.